The anticancer activity of antisense microRNA (fRNA) in combination with the lectin from Bacillus subtilis B-7025.
Many adenocarcinomas have the ability to capture from an extracellular matrix the oligonucleotides and nanoparticles by pinocytosis, when the non-cancerous cells are not capable to capture the oligonucleotides and small liposomes. This provides selective accumulation of proposed protected oligonucleotides (fRNA) in cancer cells and also provides the absence toxicity in the fRNA. For the immunotherapy, we used immunotropic 70 kDa lectin Bacillus subtilis B-7025. In vivo experiments were carried out in C57BL line mice in Lewis lung carcinoma. The cytotoxic activity, lymphocytes and macrophages were determined in vitro using the MTT assay. Animal survival rate in groups receiving either the fRNA or lectine was 70 and 40%, respectively. Combined use of fRNA and lectine has the advantage compared with the use of these drugs in monotherapy, as the anticancer efficacy of the scheme is much higher, which is manifested in the primary tumour node and metastasis inhibition.